TPN10466

Networked: 2 relevant articles (2 outcomes, 0 trials/studies)

1.	Du, Changsheng: 2 articles (01/2023 - 01/2022)
2.	Han, Mengyao: 2 articles (01/2023 - 01/2022)
3.	Jiang, Xiangrui: 2 articles (01/2023 - 01/2022)
4.	Liu, Guangyu: 2 articles (01/2023 - 01/2022)
5.	Lv, Jie: 2 articles (01/2023 - 01/2022)
6.	Saimaier, Kaidireya: 2 articles (01/2023 - 01/2022)
7.	Shen, Jingshan: 2 articles (01/2023 - 01/2022)
8.	Wang, Chun: 2 articles (01/2023 - 01/2022)
9.	Xie, Ling: 2 articles (01/2023 - 01/2022)
10.	Zhang, Yan: 2 articles (01/2023 - 01/2022)

1.	Autoimmune Diseases (Autoimmune Disease) 01/01/2023 - "In conclusion, our work suggests that TPN10466 provides protection against the autoimmune disease AIH by suppressing the inflammatory response of T cells, suggesting that TPN10466 may be a promising potential agent for the treatment of AIH." 01/01/2022 - "In conclusion, our work demonstrated that TPN10466 provided protection against the autoimmune disease EAE by inhibiting the migration of immune cells and suppressing Th1/Th17 differentiation, suggesting that TPN10466 could be a potential for promising potential agent for the treatment of MS/EAE."
2.	Autoimmune Hepatitis 01/01/2023 - "TPN10466 ameliorates Concanavalin A-induced autoimmune hepatitis in mice via inhibiting ERK/JNK/p38 signaling pathway."
3.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/2022 - "Artemisinin derivative TPN10466 suppresses immune cell migration and Th1/Th17 differentiation to ameliorate disease severity in experimental autoimmune encephalomyelitis."